2012

Mihaylova, B. et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 380(9841), pp. 581-590. (doi: 10.1016/S0140-6736(12)60367-5)

Akao, H. et al. (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 220(2), pp. 413-417. (doi: 10.1016/j.atherosclerosis.2011.09.028)

Akao, H. et al. (2012) KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 220(2), pp. 456-462. (doi: 10.1016/j.atherosclerosis.2011.11.037)

Emberson, J.R. et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE, 7(1), e29849. (doi: 10.1371/journal.pone.0029849) (PMID:22276132) (PMCID:PMC3261846)

2011

van Es, A.C.G.M. et al. (2011) Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology, 77(15), pp. 1446-1452. (doi: 10.1212/WNL.0b013e318232ab1d)

Widya, R. L. et al. (2011) Increased amygdalar and hippocampal volumes in elderly obese individuals with or at risk of cardiovascular disease. American Journal of Clinical Nutrition, 93(6), pp. 1190-1195. (doi: 10.3945/ajcn.110.006304)

Logue, J. , Murray, H.M., Welsh, P. , Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2011) Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart, 97(7), pp. 564-568. (doi: 10.1136/hrt.2010.211201)

Rahimi, K. et al. (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. British Medical Journal, 342, d1250. (doi: 10.1136/bmj.d1250)

Wensley, F. et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal, 342, d548-d548. (doi: 10.1136/bmj.d548)

Li, Y. et al. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1), pp. 17-23. (doi: 10.1007/s00439-010-0892-6)

Macfarlane, P.W., Murray, H., Sattar, N. , Stott, D.J. , Ford, I. , Buckley, B., Jukema, J.W., Westendorp, R.G.J. and Shepherd, J. (2011) The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace, 13(5), pp. 634-639. (doi: 10.1093/europace/eur016)

Mutsaerts, H.J.M.M. et al. (2011) Diastolic carotid artery wall shear stress is associated with cerebral infarcts and periventricular white matter lesions. Stroke, 42(12), pp. 3497-3501. (doi: 10.1161/STROKEAHA.111.614453)

Pons, D. et al. (2011) Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart, 97(2), pp. 143-150. (doi: 10.1136/hrt.2010.199927)

2010

Iakoubova, O.A. et al. (2010) KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(4), pp. 455-461. (doi: 10.1097/HJR.0b013e328336a0dd)

Ford, I. , Robertson, M., Shepherd, J. and Cobbe, S. (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 375(9726), pp. 1634-1639. (doi: 10.1016/S0140-6736(10)60545-4)

Caslake, M.J. et al. (2010) Lipoprotein-associated phospholipase A₂ inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 210(1), pp. 28-34. (doi: 10.1016/j.atherosclerosis.2009.10.041)

Polisecki, E. et al. (2010) Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 51(5), pp. 1201-1207. (doi: 10.1194/jlr.P001172)

Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)

Matthan, N.R., Resteghini, N., Robertson, M., Ford, I. , Shepherd, J., Packard, C. , Buckley, B.M., Jukema, J.W., Lichenstein, A.H. and Schaefer, E.J. (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 51, pp. 202-209. (doi: 10.1194/jlr.M900032-JLR200)

Trompet, S. et al. (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 257(1), pp. 85-90. (doi: 10.1007/s00415-009-5271-7)

Welsh, P. et al. (2010) Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach. Journal of Clinical Endocrinology and Metabolism, 95(1), pp. 93-99. (doi: 10.1210/jc.2009-1064)

Preiss, D. , Welsh, P. , Murray, H., Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi: 10.1093/eurheartj/ehq095)

Stott, D.J. et al. (2010) Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), pp. 605-611. (doi: 10.1161/ATVBAHA.109.199448)

2009

Trompet, S. et al. (2009) Apolipoprotein E genotype, plasma cholesterol, and cancer: a mendelian randomization study. American Journal of Epidemiology, 170(11), pp. 1415-1421. (doi: 10.1093/aje/kwp294)

Shepherd, J., Lowe, G., Ford, I. and Robertson, M. (2009) Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Statistics in Medicine, 28(7), pp. 1067-1092. (doi: 10.1002/sim.3530)

Welsh, P. et al. (2009) Leptin Predicts Diabetes but Not Cardiovascular Disease Results from a large prospective study in an elderly population. Diabetes Care, 32(2), pp. 308-310. (doi: 10.2337/dc08-1458)

Ford, I. et al. (2009) Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Medicine, 6(1), e1000016. (doi: 10.1371/journal.pmed.1000016)

Sattar, N.A. et al. (2009) Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Medicine, 6(6), e1000099. (doi: 10.1371/journal.pmed.1000099)

Sattar, N. et al. (2009) Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia, 52(2), pp. 235-239.

2008

Polisecki, E. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response and cardiovascular disease incidence in PROSPER. Atherosclerosis, 200(1), pp. 109-114.

Sattar, N. et al. (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, 371(9628), pp. 1927-1935. (doi: 10.1016/S0140-6736(08)60602-9)

Downs, J.R. et al. (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), pp. 117-125. (doi: 10.1016/S0140-6736(08)60104-X)

Takagi, T. et al. (2008) Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 196(1), pp. 114-121. (doi: 10.1016/j.atherosclerosis.2007.02.013)

Belch, J. et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. British Medical Journal, 337, a1840. (doi: 10.1136/bmj.a1840)

Shepherd, J. (2008) Monotherapy vs combination therapy for dyslipidemia in the elderly. American Journal of Geriatric Cardiology, 17(2), pp. 108-113.

Trompet, S. et al. (2008) Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Experimental Gerontology, 43(8), pp. 801-805. (doi: 10.1016/j.exger.2008.04.006)

Trompet, S. et al. (2008) Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain, 131(4), pp. 1069-1077. (doi: 10.1093/brain/awn023)

2007

Packard, C.J. et al. (2007) Association between apolipoprotein E4 and cognitive decline in elderly adults. Journal of the American Geriatrics Society, 55(11), pp. 1777-1785. (doi: 10.1111/j.1532-5415.2007.01415.x)

Shepherd, J. (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism, 9(5), pp. 609-616. (doi: 10.1111/j.1463-1326.2006.00642.x) (PMID:17697054)

Sattar, N. , McConnachie, A. , Ford, I. , Gaw, A., Cleland, S.J., Forouhi, N.G., Macfarlane, P., Shepherd, J., Cobbe, S. and Packard, C. (2007) Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study - Specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes, 56(4), pp. 984-991. (doi: 10.2337/db06-1256)

Ford, I., Murray, H., Shepherd, J., Packard, C. , Macfarlane, P. and Cobbe, S. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine, 357(15), pp. 1477-1486. (doi: 10.1056/NEJMoa065994)

Sattar, N. et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation, 115(8), pp. 981-989. (doi: 10.1161/CIRCULATIONAHA.106.643114)

Trompet, S. et al. (2007) Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events - The PROSPER study. In: Rattan, S. and Akman, S. (eds.) Biogerontology: Mechanisms and Interventions. Series: Annals of the New York Academy of Sciences (1100). Blackwell Publishing: Oxford, pp. 189-198. ISBN 978-1-57331-679-8 (doi: 10.1196/annals.1395.018)

2006

Deedwania, P. et al. (2006) Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet, 368(9539), pp. 919-928. (doi: 10.1016/S0140-6736(06)69292-1)

Iakoubova, O.A. et al. (2006) Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations - CARE and WOSCOPS. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(12), pp. 2763-2768.

Ilkova, H., Pedersen, T. and Shepherd, J. (2006) Proceedings of the 2nd International Merck Symposium on HDL-C Raising - Bridging the gap in cardiovascular risk reduction: A call to action - Barcelona, 14-15 October, 2005 - Guest editorial. European Heart Journal Supplements, 8(F), F3-F3.

Shepherd, J. (2006) Who should receive a statin these days? Lessons from recent clinical trials. Journal of Internal Medicine, 260(4), pp. 305-319.

Shepherd, J. et al. (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes - The treating to new targets (TNT) study. Diabetes Care, 29(6), pp. 1220-1226. (doi: 10.2337/dc05-2465)

Tonelli, M. et al. (2006) Letter regarding article by Tonelli et al, 'Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease' - Response. Circulation, 113(4), E59-E60.

2005

Assmann, G., Chapman, J. and Shepherd, J. (2005) Proceedings of the international Merck symposium on HDL raising beyond LDL-C reduction: New paradigms in the reduction of cardiovascular risk Rome, 1-2 October, 2004 - Introduction. European Heart Journal Supplements, 7(F), F3-F3.

Ballantyne, C., Arroll, B. and Shepherd, J. (2005) Lipids and CVD management: towards a global consensus. European Heart Journal, 26(21), pp. 2224-2231.

Larosa, J. et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 352(14), pp. 1425-1435.

Packard, C.J. et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112, pp. 3058-3065. (doi: 10.1161/CIRCULATIONAHA.105.526848)

Shepherd, J. (2005) Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? Atherosclerosis Supplements, 6(3), pp. 15-19.

Shepherd, J., Betteridge, J. and Van Gaal, L. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion, 21(5), pp. 665-682.

Shepherd, J. (2005) Ezetimibe. In: Webb, D.J., Paterson, K.R. and Flockhart, D.A. (eds.) The Year in Therapeutics. Clinical Publishing: Oxford, UK, pp. 269-291. ISBN 9781904392507

Shepherd, J. (2005) What is the best way to manage dyslipidemia? Dialogies in Cardiovascular Medicine, 5(4), pp. 249-257.

2004

Shepherd, J., Cobbe, S.M., Ford, I. , Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard, C.J. (2004) Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. Atherosclerosis Supplements, 5(3), pp. 91-97. (doi: 10.1016/j.atherosclerosissup.2004.08.029)

Gaw, A., Packard, C.J. and Shepherd, J. (Eds.) (2004) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK. ISBN 9781841842929

Chapman, M., Assmann, G., Fruchart, J., Shepherd, J. and Sirtori, C. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Current Medical Research and Opinion, 20(8), pp. 1253-1268.

Sattar, N., Scherbakova, O., Ford, I., O'Reilly, D., Stanley, A., Forrest, E., MacFarlane, P., Packard, C. , Cobbe, S. and Shepherd, J. (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes, 53(11), pp. 2855-2860. (doi: 10.2337/diabetes.53.11.2855)

Sattar, N. et al. (2004) Metabolic syndrome and diabetes mellitus - Response. Circulation, 109(3), E23-E23.

Shepherd, J. (2004) Lipids in health and disease. Biochemical Society Transactions, 32, pp. 1051-1056.

Shepherd, J. (2004) Statin therapy: a quantum advance in vascular risk management. Atherosclerosis Supplements, 5(3), pp. 33-34.

Shepherd, J. (2004) Statins for primary prevention: strategic options to save lives and money. Journal of the Royal Society of Medicine, 97(2), pp. 66-71.

Shepherd, J., Hunninghake, D., Stein, E., Kastelein, J., Harris, S., Pears, J. and Hutchinson, H. (2004) Safety of rosuvastatin. American Journal of Cardiology, 94(7), pp. 882-888.

Shepherd, J., Packard, C., Littlejohn, T., Walker, J., Stein, E., Smith, K., Kallend, D. and Blasetto, J. (2004) Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. Current Medical Research and Opinion, 20(10), pp. 1571-1578.

Shepherd, J. (2004) Primary prevention of coronary heart disease with statins. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 110-122. ISBN 9781841842929

Shepherd, J. (2004) Statin therapy for the 21st century. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 241-252. ISBN 9781841842929

Shepherd, J., Blauw, G.J., Murphy, M.G. and Gaw, A. (2004) The prospective study of pravastatin in the elderly at risk (PROSPER). In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG-CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 175-188. ISBN 9781841842929

Tonelli, M. et al. (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation, 110(12), pp. 1557-1563. (doi: 10.1161/01.CIR.0000143892.84582.60)

2003

Sattar, N. et al. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108(4), pp. 414-419. (doi: 10.1161/01.CIR.0000080897.52664.94) (PMID:12860911)

Braunwald, E. and Shepherd, J. (2003) Optimal strategies in preventing the next event: The role of statins in cardiovascular protection - Foreword. Atherosclerosis Supplements, 4(5), pp. 1-2.

Chapman, J. and Shepherd, J. (2003) Introduction: A new beginning for statin therapy? Atherosclerosis Supplements, 4(1), pp. 1-2.

Davidson, M., Wood, D., Paoletti, R., Hobbs, R., Shepherd, J., Brown, W., Hunninghake, D. and McKenney, J. (2003) Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals - Discussion. American Journal of Cardiology, 91(5A), 17C-19C.

Mungall, M., Gaw, A. and Shepherd, J. (2003) Statin therapy in the elderly - Does it make good clinical and economic sense? Drugs and Aging, 20(4), pp. 263-275.

Shepherd, J. (2003) Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. European Heart Journal, 24(8), pp. 685-689.

Shepherd, J. (2003) Preventing the next event in the elderly: the PROSPER perspective. Atherosclerosis Supplements, 4(5), pp. 17-22.

Shepherd, J. (2003) Statins: putting the benefit/risk into perspective. International Journal of Clinical Practice, pp. 27-33.

Shepherd, J. (2003) Summary. Atherosclerosis Supplements, 4(5), pp. 23-24.

Shepherd, J., Blauw, G. and Murphy, M. (2003) More on Prosper - Reply. Lancet, 361(9363), p. 1136.

Shepherd, J., Blauw, G. and Murphy, M. (2003) The PROSPER trial - Reply. Lancet, 361(9355), p. 428.

Stein, E., Shepherd, J., Barter, P. and Hobbs, R. (2003) Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin - Discussion. American Journal of Cardiology, 91(5A), 23C-24C.

2002

Shepherd, J. (2002) Diabetes in tomorrow's world: dark clouds do have silver linings. Diabetes, Obesity and Metabolism, 4(6), pp. 351-355. (doi: 10.1046/j.1463-1326.2002.00193.x) (PMID:12406030)

Cho, H., Shin, G., Ryu, S., Jang, Y., Day, S., Stewart, G., Packard, C., Shepherd, J. and Caslake, M. (2002) Regulation of small dense LDL concentration in Korean and Scottish men and women. Atherosclerosis, 164, pp. 187-193.

Ford, I. et al. (2002) A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics. Current Controlled Trials in Cardiovascular Medicine, 3, p. 8. (doi: 10.1186/1468-6708-3-8)

Forster, L., Stewart, G., Bedford, D., Stewart, J., Rogers, E., Shepherd, J., Packard, C. and Caslake, M. (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis, 164(1), pp. 129-145.

Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C. and Braunwald, E. (2002) Coronary heart disease in patients with low LDL-cholesterol - Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), pp. 1424-1428.

Shepherd, J. (2002) Fire-and-forget in prevention of coronary heart disease - Reply. Lancet, 360(9349), p. 1984.

Shepherd, J. (2002) Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet, 359(9325), pp. 2271-2273.

Shepherd, J. (2002) The statin era in cardiovascular medicine: what's next? Cardiovascular Reviews and Reports, 11, pp. 639-648.

Shepherd, J. and Barter, P. (2002) Lipid-lowering - translating evidence into benefits - Introduction. Atherosclerosis Supplements, 2(4), pp. 1-3.

Shepherd, J. et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360(9346), pp. 1623-1630. (doi: 10.1016/S0140-6736(02)11600-X)

Shepherd, J. and Gaw, A. (2002) The anatomy of a clinical trial - The West of Scotland Coronary Prevention Study. Medical Principles and Practice, 11, pp. 17-30.

Simes, J., Furberg, C., Braunwald, E., Davis, B., Ford, I. , Tonkin, A. and Shepherd, J. (2002) Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels - The Prospective Pravastatin Pooling project. European Heart Journal, 23, pp. 207-215. (doi: 10.1053/euhj.2001.2775)

Streja, L., Packard, C. , Shepherd, J., Cobbe, S. and Ford, I. (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology, 90(7), pp. 731-736. (doi: 10.1016/S0002-9149(02)02599-7)

2001

Byington, R., Davis, B., Plehn, J., White, H., Baker, J., Cobbe, S. and Shepherd, J. (2001) Reduction of stroke events with pravastatin - The Prospective Pravastatin Pooling (PPP) Project. Circulation, 103(3), pp. 387-392.

Freeman, D. et al. (2001) Pravastatin and the development of diabetes mellitus - Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103(3), pp. 357-362.

Gaw, A., Kelly, A., McMahon, A., Packard, C., Sattar, N. , Shepherd, J. and Wallace, A. (2001) Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).[see comment]. Circulation, 104(25), pp. 3052-3056.

Gaw, A. and Shepherd, J. (2001) Lipids and Atherosclerosis Annual. Martin Dunitz: London, UK. ISBN 9781853179044

Lloyd, G., Jackson, G., Foley, D., Boersma, E., Shepherd, J. and Serruys, P. (2001) The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty - Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis, 158(2), pp. 445-454.

Murphy, M. and Shepherd, J. (2001) Healthy ageing: Statin therapy opportunities - The 72nd European Atherosclerosis Society Congress - Foreword. European Heart Journal Supplements, 3(N), N1-N2.

Shepherd, J. (2001) Economics of lipid lowering in primary prevention: Lessons from the West of Scotland Coronary Prevention Study. American Journal of Cardiology, 87(5A), 19B-22B.

Shepherd, J. (2001) Issues surrounding age: vascular disease in the elderly. Current Opinion in Lipidology, 12(6), pp. 601-609.

Shepherd, J. (2001) The role of the exogenous pathway in hypercholesterolaemia. European Heart Journal Supplements, 3(E), E2-E5.

Shepherd, J. (2001) The statin era: in search of the ideal lipid regulating agent. Heart, 85(3), pp. 259-264.

Tan, C., Chew, L., Tai, E., Chio, L., Lim, H., Loh, L. and Shepherd, J. (2001) Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis, 154(2), pp. 469-474.

2000

L'Itallien, G., Ford, I. , Norrie, J., LaPuerta, P., Ehreth, J., Jackson, J. and Shepherd, J. (2000) The cardiovascular event reduction tool(CERT)- a simplified cardiac risk prediction model developed from the West of Scotland coronary prevention study (WOSCOPS). American Journal of Cardiology, 85(6), pp. 720-724. (doi: 10.1016/S0002-9149(99)00847-4) (PMID:12000046)

Lowe, G., Rumley, A., Norrie, J., Ford, I. , Shepherd, J., Cobbe, S., Macfarlane, P. and Packard, C. (2000) Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thrombosis and Haemostasis, 84(4), pp. 553-558.

1995

Shepherd, J., Cobbe, S.M., Ford, I. , Isles, C.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H. and Packard, C.J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine, 333(20), pp. 1301-1308. (doi: 10.1056/NEJM199511163332001)